Phibro Animal Health

Phibro Animal Health Corp. engages in the manufacture and supply of animal health and mineral nutrition products. It operates through the following segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment develops and markets antibacterial, nutritional specialty products, and vaccines. The Mineral Nutrition segment consists of the formulations and concentrations of trace minerals such as zinc, manganese, copper, iron, and compounds. The Performance Products segment produces specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company was founded on May 11, 1946 and is headquartered in Teaneck, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

PAHC reports Q3 sales growth, addresses challenges and opportunities

PAHC's Q3 2023 earnings call highlighted strong sales growth in the Animal Health segment, while facing challenges in the Mineral Nutrition segment. The company reiterated its full-year guidance and discussed various opportunities for growth and expansion.

Phibro Animal Health reports Q2 growth, adjusts guidance for 2023

Phibro Animal Health (PAHC) showed overall growth in net sales and adjusted EBITDA despite challenges in certain regions and segments.
The company remains focused on its full-year guidance but adjusted GAAP expectations due to environmental factors.
Strategic investments and market opportunities present avenues for future growth and performance improvement.

Phibro Animal Health reports strong Q3 sales growth and margin improvement

Phibro Animal Health Corporation demonstrated robust sales growth and margin improvement in the Animal Health segment, while facing challenges related to negative free cash flow. Despite this, the company remains optimistic about meeting its full-year guidance and sees opportunities for growth through market expansion and operational enhancements.

Phibro Animal Health reports strong FY 2023 performance and projects continued growth in Animal Health segment

Phibro Animal Health delivered solid financial performance in FY 2023, with a strong outlook for FY 2024 driven by growth in the Animal Health segment.
Strategic investments in vaccines and companion animals position the company for continued expansion and margin maintenance amidst challenges.
Efforts to enhance operational efficiency and cash flow generation underscore a commitment to sustainable growth and financial strength.
Anticipated top and bottom-line growth, along with market stability, signal a positive trajectory for Phibro Animal Health in the upcoming fiscal year.

Phibro Animal Health reports mixed Q1 results amid market challenges

Phibro Animal Health's Q1 2024 performance was marked by growth in the Animal Health segment but challenges in other segments.
Efforts to manage working capital effectively and maintain a stable financial position are key strengths.
However, declines in adjusted EBITDA, revenue, and margins present hurdles that require strategic solutions.
Opportunities for growth lie in addressing challenges across segments and exploring innovative market strategies.

Phibro Animal Health reports Q2 growth, affirms guidance amid challenges

Phibro Animal Health's Q2 2024 performance reflects solid growth in net sales driven by the Animal Health segment, despite challenges in other segments.
The company's ability to manage operational challenges in Israel and maintain guidance reaffirm confidence in its strategic direction and resilience.
With positive demand trends and a new CFO onboard, Phibro Animal Health is poised to leverage opportunities for growth and operational excellence.

Phibro Animal Health reports robust Q3 performance and strategic acquisitions

Phibro Animal Health (PAHC) delivered a strong Q3 performance with notable growth in total company and Animal Health sales, supported by positive financial metrics and strategic acquisitions.
While facing integration challenges and competitive pressures, the company's strengths in market performance, financial health, and strategic guidance position it well for future growth.
Opportunities in product expansion, market diversification, and innovation present avenues for sustained growth and market leadership in the animal health industry.

Phibro Animal Health posts strong Q4 results, eyes Zoetis acquisition

Phibro Animal Health (PAHC) delivered robust financial results in Q4 2024, driven by growth in key segments and operational improvements.
The pending Zoetis MFA acquisition and successful refinancing demonstrate Phibro's strategic focus on expansion and financial strength.
While challenges in integration and regulatory approvals exist, Phibro is well-positioned to capitalize on opportunities for market expansion and sustained growth.
Investors can look forward to Phibro's continued performance and value creation as it navigates industry dynamics and executes on its strategic initiatives.

Phibro Animal Health reports stellar Q1 results and eyes growth

Phibro Animal Health delivered impressive Q1 2025 results, showcasing robust financial growth and strategic acquisitions.
While facing challenges such as margin concerns and project discontinuations, the company remains optimistic about its future prospects.
By capitalizing on opportunities in the acquired portfolio and focusing on operational excellence, Phibro aims to sustain its growth trajectory and drive shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Phibro Animal Health Corp. engages in the development, manufacture, and marketing of animal health and mineral nutrition products. It operates through the following segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment develops and markets medicated feed additives, nutritional specialty products, and vaccines. The Mineral Nutrition segment includes formulations and concentrations of trace minerals such as zinc, manganese, copper, iron, and compounds. The Performance Products segment produces specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company was founded on May 11, 1946 and is headquartered in Teaneck, NJ.

Phibro Animal Health Corporation (PAHC) CEO Jack Bendheim on Q4 2020 Results - Earnings Call Transcript

Phibro's (PAHC) core Animal Health segment was aided by the Osprey Biotechnics acquisition despite a dismal overall performance in Q4 due to pandemic-led business disruptions.

Phibro (PAHC) Q4 Earnings Fall Short of Estimates, Margins Up

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (NASDAQ:PAHC) today announced its financial results for its fourth quarter and fiscal year ended June 30, 2020.

Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Guidance for Its Fiscal First Quarter

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its fourth quarter and fiscal year 2020 financial results on Wednesday, August 26, 2020, after the market closes.

Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2020 Results

TEANECK, N.J.--(BUSINESS WIRE)--(NASDAQ:PAHC) Today, the Food and Drug Administration (FDA) provided notice of Federal Register publication of its intention to take a number of actions related to its ongoing review of the regulatory status of Mecadox® (carbadox).

Phibro Animal Health Corporation Reiterates Safety of Mecadox®

Merck

PetMed Express

Spending on pet health continues to climb. Investors should consider buying PetMed Express, Phibro Animal Health, and Merck & Co.

3 Pet Med Stocks That Offer Growth and a Nice Dividend

Phibro (PAHC) witnessed revenue uptick in its core Animal Health segment in Q3 despite the coronavirus-led business disruptions in the animal production industry.

Phibro (PAHC) Q3 Earnings Surpass Estimates, Margin Declines

Phibro Animal Health Corporation (PAHC) CEO Jack Bendheim on Q3 2020 Results - Earnings Call Transcript

Phibro (PAHC) reported earnings 30 days ago. What's next for the stock?

Why Is Phibro (PAHC) Down 7.9% Since Last Earnings Report?

Perrigo

PRGO vs. PAHC: Which Stock Is the Better Value Option?

PRGO or PAHC: Which Is the Better Value Stock Right Now?

The company raised guidance, and also raised hopes about its vaccine candidate for African swine fever.

Phibro Animal Health Soars on Better-Than-Expected Earnings

Phibro Animal Health Corporation (PAHC) CEO Jack Bendheim on Q2 2020 Results - Earnings Call Transcript

Phibro (PAHC) witnessed revenue decline in two of its core segments and contraction in operating margin in Q2.

Phibro (PAHC) Q2 Earnings Top Estimates, Revenues Fall Y/Y

PRGO vs. PAHC: Which Stock Should Value Investors Buy Now?

Investors can retain Phibro (PAHC) stock for now, thanks to its solid prospects.

Here's Why You Should Hold on to Phibro (PAHC) Stock Now

Why Is Phibro (PAHC) Up 8.5% Since Last Earnings Report?

Phibro Animal Health Corporation (PAHC) CEO Jack Bendheim on Q1 2020 Results - Earnings Call Transcript

Phibro (PAHC) exhibits a dismal first-quarter performance on a decline in revenues at core business segments.

Phibro's (PAHC) Q1 Earnings & Revenues Fall Y/Y, Margins Down

Per Phibro Animal (PAHC), weak demand in Animal Health business due to swine flu outbreak in China along with an unfavorable product mix in Mineral Nutrition is dampening.

Phibro (PAHC) Suffers Dismal Segmental Sales, Margin Woes

Why Is Phibro (PAHC) Up 0.4% Since Last Earnings Report?

The company will not slow investment despite a rough patch caused by African swine fever.

Why Shares of Phibro Animal Health Crashed Today

Autodesk

Movado Group

Despite a nice move higher for the major benchmarks, these stocks missed out on the rally.

Why Movado Group, Phibro Animal Health, and Autodesk Slumped Today

Phibro Animal Health Corporation (PAHC) CEO Jack Bendheim on Q4 2019 - Earnings Call Transcript

Phibro's (PAHC) revenue decline across two core segments and contraction in operating margin are concerning.

Phibro's (PAHC) Q4 Earnings Miss Estimates, Revenues Fall Y/Y

Phibro Animal Health Corp. PAHC, -0.60% shares plummeted in the extended session Tuesday after the animal health and nutrition-products maker missed Wall Street estimates and said demand from China has declined due to an outbreak of swine fever.

News for Phibro Animal Health Stock (PAHC)